Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Slideshows|December 2, 2019
Year in Review: 2019 Special Reports in Psychiatry
Author(s)Heidi Anne Duerr, MPH, Laurie Martin
As varied as the field of psychiatry itself, our Special Report collections covered issues such as eating disorders, traumatic brain injury, practice management, schizophrenia and depression, complex medical comorbidities, and more. Here's a sampling.
Advertisement
Advertisement
Related to this article
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Vortioxetine's Effect on Cognitive Function in Older Adults With Major Depressive Disorder
3
Interventional Options for TRD: ECT, TMS, and Esketamine
4
Muscarinic Treatment for Schizophrenia: A Presynaptic Answer to a Presynaptic Problem
5